Forest gets small-molecule pain candidates from Grunenthal; GRT6005/cebranopadol part ended
In their second partnership, Grunenthal GMBH (mid-sized European drug company focused on pain management) has licensed Forest Laboratories Inc. exclusive US and Canadian rights to its pain compounds GRT6005 (cebranopadol) and GRT6006 (lexanopadol). Forest also received a European co-promotion option.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.